- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03110952
TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Single-Center, Study of TDENV-PIV and TDENV-F17 Dengue Vaccine Platforms in a Heterologous Prime Boost Strategy in Healthy Adults in a Non-Endemic Region
The potential synergistic effect of administering 2 dengue vaccine candidates that were previously shown to be safe and immunogenic in humans will be evaluated in this study. A prime-boost study of tetravalent dengue virus purified inactivated vaccine (TDENV-PIV) with the GSK AS03B adjuvant and tetravalent dengue live attenuated virus (TDENV-LAV) vaccine Formulation 17 (F17) will gather data to help better understand the human immune response to dengue vaccination and infection.
This study is being done to evaluate the safety and immune reaction of administering one dose of dengue purified inactivated vaccine and one dose of dengue live attenuated vaccine compared to two doses of inactivated vaccine.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
Syracuse, New York, United States, 13210
- Upstate Medical University, SUNY
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects who in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., document events in memory aid, return for follow-up visits, etc.)
- Between 18 and 39 years of age (inclusive) at the time of consent
- Written informed consent obtained from the subject
- Healthy subjects as established by medical history and clinical examination before entering into the study.
Exclusion Criteria:
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines/placebo during the period starting 30 days preceding the first dose of study vaccine/placebo and/or planned use during the study period
- Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 180 days prior to the first vaccine/placebo dose (for corticosteroids, this will mean prednisone 20 mg/day or equivalent; inhaled and topical steroids are allowed)
- Planned administration or administration of a vaccine/product not foreseen by the study protocol during the period starting 30 days before or after each scheduled dose of an investigational product or placebo.
- Planned administration of any flavivirus vaccine for the entire study duration
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or an approved/cleared non-investigational product (pharmaceutical product or device).
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- Family history of congenital or hereditary immunodeficiency
- History and family history of a bleeding disorder
- History of past flavivirus infection or vaccination (Yellow Fever, tick-borne encephalitis virus (TBEV), Japanese encephalitis virus (JEV), West Nile virus (WNV), dengue (DENV)
- History of, or current, auto-immune disease
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine/placebo or related to a study procedure
- Major congenital defects or serious chronic illness
- History of any neurological disorders or seizures
- Acute disease and/or fever (≥ 100.4° ◦F / 38.0° ◦C, oral body temperature) at the time of enrollment (a subject with a minor illness, i.e., mild diarrhea, mild upper respiratory infection, etc., without fever, may be enrolled at the discretion of the investigator)
- Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination or laboratory screening tests
- Administration of immunoglobulins and/or any blood products during the period starting 90 days preceding the first dose of study vaccine/placebo or planned administration during the study period
- History of chronic alcohol consumption and/or drug abuse
- A planned move to a location that will prohibit participating in the trial until study end for the participant
- Any other condition which, in the opinion of the investigator, prevents the subject from participating in the study.
- Subject seropositive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), or human immunodeficiency virus antibodies (anti-HIV)
- Safety laboratory test results that are outside the acceptable values at screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TDENV-PIV x2
2 doses of TDENV-PIV on Day 0 and Day 28
|
Single-dose vial with pre-filled syringe, subcutaneous injection
Other Names:
|
Experimental: TDENV-F17/TDENV-PIV
1 dose TDENV-F17 on Day 0 and 1 dose TDENV-PIV on Day 28
|
Single-dose vial with pre-filled syringe, subcutaneous injection
Other Names:
Single-dose vial with pre-filled syringe 0.5 mL administered intramuscularly
Other Names:
|
Experimental: TDENV-PIV/TDENV-F17
1 dose TDENV-PIV on Day 0 and 1 dose TDENV-F17 on Day 28
|
Single-dose vial with pre-filled syringe, subcutaneous injection
Other Names:
Single-dose vial with pre-filled syringe 0.5 mL administered intramuscularly
Other Names:
|
Placebo Comparator: Placebo
2 doses placebo (phosphate buffered saline) Day 0 and Day 28
|
0.5 mL vial
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of and intensity of solicited local and general adverse events (AEs) during the 7-day follow-up period after each vaccination
Time Frame: Day 7 and Day 35
|
Day 7 and Day 35
|
|
Number of and intensity of unsolicited adverse events (AEs) during the 7-day follow-up period after each vaccination
Time Frame: Day 7 and Day 35
|
Day 7 and Day 35
|
|
Number of serious adverse events (SAEs)
Time Frame: Day 35
|
Day 35
|
|
Number of potential immune-mediated diseases (pIMDs) and medicall attended AEs
Time Frame: Day 56
|
Day 56
|
|
Geometric mean titers (GMTs) of neutralizing antibodies to each DENV serotype
Time Frame: Day 56
|
Assessment of neutralizing antibodies against DENV type 1-4 will be performed by a validated microneutralizing antibody assay.
|
Day 56
|
Number of participants seropositive for each DENV serotype
Time Frame: Day 56
|
Seropositive will be determined by 50% reduction in viral infection (MN50)
|
Day 56
|
Number of participants trivalent and tetravalent seropositive
Time Frame: Day 56
|
Seropositive will be determined by 50% reduction in viral infection (MN50)
|
Day 56
|
Collaborators and Investigators
Investigators
- Principal Investigator: Mark Polhemus, Upstate Medical University, SUNY
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Arbovirus Infections
- Vector Borne Diseases
- Flavivirus Infections
- Flaviviridae Infections
- Hemorrhagic Fevers, Viral
- Dengue
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Immunologic Factors
- Protective Agents
- Micronutrients
- Vitamins
- Antioxidants
- Vaccines
- alpha-Tocopherol
Other Study ID Numbers
- S-14-08
- DPIV-020 (Other Identifier: Sponsor)
- 201126 (GSK eTrack)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dengue
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesMexico
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseaseVietnam
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesPeru
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesSingapore
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesThailand
-
U.S. Army Medical Research and Development CommandGlaxoSmithKlineCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Shock SyndromePuerto Rico
-
University of the PhilippinesWorld Health Organization; University of North Carolina; International Vaccine... and other collaboratorsActive, not recruitingDengue | Dengue Fever | Severe Dengue | Virologically-confirmed Dengue
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue VirusPuerto Rico, Colombia, Mexico, Honduras
-
SanofiCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue VirusUnited States
-
SanofiCompletedDengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue VirusAustralia
Clinical Trials on TDENV-PIV
-
U.S. Army Medical Research and Development CommandActive, not recruiting
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)Completed
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)Completed
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)Completed
-
U.S. Army Medical Research and Development CommandCompleted
-
3MTerminated
-
U.S. Army Medical Research and Development CommandCompletedDengue FeverUnited States
-
University of Texas at AustinNot yet recruitingPediatric ALL
-
C. R. BardCompletedVascular Access ComplicationUnited States
-
Brooke Army Medical CenterRecruitingPerioperative Care | Procedural Pain | Procedural AnxietyUnited States